Iovance Biotherapeutics, Inc. (IOVA)
Automate Your Wheel Strategy on IOVA
With Tiblio's Option Bot, you can configure your own wheel strategy including IOVA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IOVA
- Rev/Share 0.722
- Book/Share 2.0881
- PB 1.2164
- Debt/Equity 0.0761
- CurrentRatio 3.2713
- ROIC -0.5225
- MktCap 919109160.0
- FreeCF/Share -0.9672
- PFCF -2.8408
- PE -2.1791
- Debt/Assets 0.0586
- DivYield 0
- ROE -0.5287
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | IOVA | Goldman | Neutral | Sell | -- | $1 | July 15, 2025 |
| Downgrade | IOVA | UBS | Buy | Neutral | -- | $2 | May 16, 2025 |
| Downgrade | IOVA | Truist | Buy | Hold | -- | -- | May 12, 2025 |
| Downgrade | IOVA | Citizens JMP | Mkt Outperform | Market Perform | -- | -- | May 9, 2025 |
News
Contact Levi & Korsinsky by July 14, 2025 to Join Class Action Against Iovance Biotherapeutics, Inc. (IOVA)
Published: May 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 16, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=148869&wire=1&utm_campaign=10 or contact Joseph E. Levi, Esq.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
Published: May 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ:IOVA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
IOVA CLASS ACTION NOTICE: The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against Iovance Biotherapeutics, Inc.
Published: May 16, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--IOVA CLASS ACTION NOTICE: The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against Iovance Biotherapeutics, Inc.
Read More
IOVA CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit On Behalf Of Iovance Biotherapeutics, Inc. Investors
Published: May 16, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), announces that it has filed a class action lawsuit in the United States District Court for the Northern District of California, captioned Farberov v. Iovance Biotherapeutics, Inc., et al., Case No. 25-cv-4199, on behalf of persons and entities that purchased or otherwise acquired Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA) securities between May 9, 2024 and May 8, 2025, inclusive (the “Class Per.
Read More
Fraud Investigation: Levi & Korsinsky Investigates Iovance Biotherapeutics, Inc. (IOVA) on Behalf of Shareholders
Published: May 15, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Iovance Biotherapeutics, Inc. ("Iovance Biotherapeutics, Inc.") (NASDAQ:IOVA) concerning possible violations of federal securities laws. On May 8, 2025, after the market closed, Iovance issued their first quarter fiscal 2025 results well below expectations, announcing a loss of 36 cents per share on revenue of $49 million.
Read More
Lovance Biotherapeutics' (IOVA) Annual Maintenance: Assurances Collide with Adverse Disclosure as Shares Plunge 44% - Hagens Berman
Published: May 15, 2025 by: Accesswire
Sentiment: Neutral
IOVA Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO, CA / ACCESS Newswire / May 15, 2025 / In a dramatic turn for Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), investors watched the company's shares plunge nearly 44% on May 9, 2025, after the San Carlos-based cell therapy pioneer reported a first-quarter revenue miss that sharply contradicted earlier upbeat assurances from management. Hagens Berman is now investigating whether Iovance violated U.S. securities laws and urges Iovance investors who suffered substantial losses to submit your losses now.
Read More
Levi & Korsinsky Investigates Iovance Biotherapeutics, Inc. (IOVA) Over Potential Securities Fraud Allegations
Published: May 15, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Iovance Biotherapeutics, Inc. ("Iovance Biotherapeutics, Inc.") (NASDAQ:IOVA) concerning possible violations of federal securities laws. On May 8, 2025, after the market closed, Iovance issued their first quarter fiscal 2025 results well below expectations, announcing a loss of 36 cents per share on revenue of $49 million.
Read More
Levi & Korsinsky Investigates Iovance Biotherapeutics, Inc. (IOVA) Over Possible Securities Fraud
Published: May 14, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Iovance Biotherapeutics, Inc. ("Iovance Biotherapeutics, Inc.") (NASDAQ:IOVA) concerning possible violations of federal securities laws. On May 8, 2025, after the market closed, Iovance issued their first quarter fiscal 2025 results well below expectations, announcing a loss of 36 cents per share on revenue of $49 million.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
Published: May 14, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ:IOVA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Ongoing Investigation: Iovance Biotherapeutics, Inc. (IOVA) May Have Misled Shareholders - Levi & Korsinsky Investigates
Published: May 14, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Iovance Biotherapeutics, Inc. ("Iovance Biotherapeutics, Inc.") (NASDAQ:IOVA) concerning possible violations of federal securities laws. On May 8, 2025, after the market closed, Iovance issued their first quarter fiscal 2025 results well below expectations, announcing a loss of 36 cents per share on revenue of $49 million.
Read More
Iovance Biotherapeutics, Inc. (IOVA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Published: May 14, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ:IOVA). Investors who purchased Iovance securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/IOVA.
Read More
Lost Money on Lovance Biotherapeutics, Inc. (IOVA)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
Published: May 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Iovance Biotherapeutics, Inc. ("Iovance Biotherapeutics, Inc.") (NASDAQ:IOVA) concerning possible violations of federal securities laws. On May 8, 2025, after the market closed, Iovance issued their first quarter fiscal 2025 results well below expectations, announcing a loss of 36 cents per share on revenue of $49 million.
Read More
Levi & Korsinsky Reminds Iovance Biotherapeutics, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - IOVA
Published: May 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Iovance Biotherapeutics, Inc. ("Iovance Biotherapeutics, Inc.") (NASDAQ:IOVA) concerning possible violations of federal securities laws. On May 8, 2025, after the market closed, Iovance issued their first quarter fiscal 2025 results well below expectations, announcing a loss of 36 cents per share on revenue of $49 million.
Read More
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Iovance Biotherapeutics, Inc. (IOVA) and Encourages Stockholders to Learn More About the Investigation
Published: May 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ:IOVA). Investors who purchased Iovance securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/IOVA.
Read More
Iovance Biotherapeutics' (IOVA) Annual Maintenance: Assurances Collide with Adverse Disclosure as Shares Plunge 44% – Hagens Berman
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, May 12, 2025 (GLOBE NEWSWIRE) -- In a dramatic turn for Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), investors watched the company's shares plunge nearly 44% on May 9, 2025, after the San Carlos-based cell therapy pioneer reported a first-quarter revenue miss that sharply contradicted earlier upbeat assurances from management.
Read More
Iovance Biotherapeutics: Abysmal Q1 2025 Performance Creates Buying Opportunity
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Positive
Iovance Biotherapeutics' stock plummeted 45% after a Q1 earnings miss, driven by temporary manufacturing issues and reduced revenue guidance. Management expects a rebound in Q2 with resumed full manufacturing capacity and increased commercial infusions, potentially leading to a positive earnings surprise. Despite the Q1 setback, Iovance's early adoption, expanding treatment network, and international regulatory prospects indicate strong long-term growth potential.
Read More
Securities Fraud Investigation Into Iovance Biotherapeutics, Inc. (IOVA) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Published: May 09, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON IOVANCE BIOTHERAPEUTICS, INC. (IOVA), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On May 8, 2025, Iovance released its first qu.
Read More
Iovance Stock Sinks 46%. Here's Why the Biotech Is Tumbling.
Published: May 09, 2025 by: Barrons
Sentiment: Negative
The oncology drug maker posts a wider-than-expected loss in the first quarter.
Read More
No Excuses, Iovance Biotherapeutics' Amtagvi Launch Has Underperformed
Published: May 09, 2025 by: Seeking Alpha
Sentiment: Negative
IOVA's Q1'25 product revenue was $49.3M, impacted by production facility maintenance; however, Q2'25 estimates for infusions imply weak growth, despite not being impacted by production. Replimune's RP1 could be approved in July 2025, providing market competition for melanoma patients. Obsidian Therapeutics will present phase 1 data from the Agni-01 trial of their cell therapy OBX-115 at ASCO 2025 on June 2.
Read More
Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Negative
IOVA reports dismal first-quarter results. The share price plunges after the company significantly lowers its 2025 sales guidance.
Read More
Iovance Biotherapeutics, Inc. (IOVA) Q1 2025 Earnings Call Transcript
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Sara Pellegrino - SVP, IR and Corporate Communications Fred Vogt - Interim CEO and President Dan Kirby - CCO Igor Bilinsky - COO Jean-Marc Bellemin - CFO Friedrich Graf Finckenstein - CMO Brian Gastman - EVP, Medical Affairs Conference Call Participants Andrew Tsai - Jefferies Tyler Van Buren - TD Cowen Salim Syed - Mizuho Andrea Newkirk - Goldman Sachs Yanan Zhu - Wells Fargo Colleen Kusy - Baird Peter Lawson - Barclays Reni Benjamin - Citizens Operator Good day and thank …
Read More
My 3 Favorite Stocks to Buy Right Now
Published: May 06, 2025 by: The Motley Fool
Sentiment: Positive
Veteran investors know that the market's recent weakness is more of an opportunity than an omen. Sure, stocks may not have hit their ultimate bottom just yet.
Read More
2 Beaten-Down Stocks With Incredible Upside Potential
Published: April 30, 2025 by: The Motley Fool
Sentiment: Positive
Iovance Biotherapeutics (IOVA -1.52%) and CRISPR Therapeutics (CRSP -1.27%) are two incredibly innovative biotechs, but this hasn't translated into strong performances recently. Both stocks have significantly lagged the market over the past three years due to a combination of factors.
Read More
Down Nearly 80% From Its High, Is Iovance Biotherapeutics Stock Too Cheap to Pass Up?
Published: March 12, 2025 by: The Motley Fool
Sentiment: Negative
When a stock is in a freefall, there's usually a justifiable reason for the decline. But for investors with a high risk tolerance, it could make for a potentially attractive contrarian play.
Read More
Iovance's Q4: Execution Risks Mount As Infusion Growth Slows (Rating Downgrade)
Published: February 28, 2025 by: Seeking Alpha
Sentiment: Negative
Iovance Biotherapeutics, Inc.'s valuation has halved since August; Amtagvi, its FDA-approved TIL therapy, generated $12.8M in initial revenue, but faces significant risks. Q3 and Q4 performances showed mixed results, with $42.1M and $48.7M in Amtagvi revenues, respectively, and a notable cash burn. Despite high costs and competition, Amtagvi remains a preferred option in PD-1-refractory melanoma, with plans to increase its price for better margins.
Read More
Iovance Biotherapeutics, Inc. (IOVA) Q4 2024 Earnings Call Transcript
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA ) Q4 2024 Earnings Conference Call February 27, 2024 4:30 PM ET Company Participants Sara Pellegrino - SVP, IR and Corporate Communications Fred Vogt - Interim CEO and President Dan Kirby - CCO Igor Bilinsky - COO Jean-Marc Bellemin - CFO Friedrich Graf Finckenstein - CMO Conference Call Participants Andrea Newkirk - Goldman Sachs Peter Lawson - Barclays Ben Burnett - Stifel Colleen Kusy - Baird Yanan Zhu - Wells Fargo Securities Asthika Goonewardene - Truist Reni Benjamin - Citizens JMP David Dai - UBS Andrew Tsai - Jefferies Operator Good day and thank you for …
Read More
Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Tops Revenue Estimates
Published: February 27, 2025 by: Zacks Investment Research
Sentiment: Negative
Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.45 per share a year ago.
Read More
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Fourth Quarter and Full Year 2024
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
Significant Demand for Amtagvi® (Lifileucel) Continues with Total Product Revenue of $73.7M in 4Q24 and $164.1M in FY24, Achieving Upper End of FY24 Guidance Range of $160M-$165M
Read More
What's in Store for These 5 Biotech Stocks This Earnings Season?
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Neutral
Let's look at five biotech and drug companies, VTRS, PRGO, NVAX, NTLA and IOVA, slated to release their fourth-quarter 2024 results on Feb. 27, 2025.
Read More
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates on February 27, 2025
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN CARLOS, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its fourth quarter and full year 2024 financial results and corporate updates on Thursday, February 27, 2025.
Read More
About Iovance Biotherapeutics, Inc. (IOVA)
- IPO Date 2010-10-15
- Website https://www.iovance.com
- Industry Biotechnology
- CEO Frederick G. Vogt
- Employees 838